Ultherapy PRIME vs Ultherapy: What Actually Changed?

Ultherapy PRIME is documented as a newer console for the Ulthera System, not as a new clinical outcome claim. In the US FDA's 2024 510(k) record, PRIME and the earlier predicate use identical ultrasound signal energy and treatment guidelines, with the same intended use, indications, main components and imaging mode. The documented changes concern the console design, display, interface and updated hardware. The FDA record does not show that PRIME produces a better clinical result.

Searches for “Ultherapy PRIME vs Ultherapy” often mix together three separate questions: whether the treatment changed, whether the operator experience changed, and whether patients should expect a better outcome. The public records answer the first two. They do not establish the third.

The documented differences at a glance

Source: the 510(k) summary published in FDA's K233996, especially its device description and substantial-equivalence table on PDF pages 5–8.

What stayed the same

The 510(k) summary says PRIME and the predicate share the same intended use and US indications. It also says they use identical ultrasound signal energy and treatment guidelines, the same console-handpiece-transducer component structure, and the same imaging mode. Most directly, the 510(k) summary says the differences do not significantly affect clinical functionality or performance specifications.

That wording is the most useful answer for a prospective patient. PRIME modernizes how the system is presented and operated. The 510(k) record does not describe a new treatment mechanism or a clinically superior result. It also does not compare individual practitioners, treatment plans or patient outcomes.

What the PRIME console changes

The 510(k) summary documents a larger, higher-resolution display, a modernized graphical interface, updated hardware and a newer operating system. The manufacturer's PRIME product page also describes a tiltable capacitive touchscreen, an integrated work surface, quieter system sounds and faster ultrasound-image refresh. Those are product and workflow descriptions from the manufacturer. They should not be converted into a claim of better lifting, longer-lasting results, less pain or improved safety.

What the US FDA record means—and what it does not

K233996 is a US 510(k) clearance dated February 22, 2024. FDA determined that the modified Ulthera System was substantially equivalent to its legally marketed predicate for the indications stated in the record. A 510(k) clearance is not a premarket approval, and this US record does not establish clearance, licensing or permitted advertising claims in Korea or any other jurisdiction.

The performance section describes non-clinical software, usability, mechanical, electrical, packaging and ultrasound-output testing. It does not report a head-to-head patient trial of PRIME versus the earlier console. That is why the honest comparison stops at the documented system and workflow changes. For the treatment mechanism itself, see what Ultherapy is and how MFU-V works.

Questions to ask before booking

• Which Ulthera console will be used for my appointment?
• Who will assess me, plan the treatment and operate the system?
• How will the treatment area and goals be chosen for me?
• How will ultrasound visualization be used during treatment?
• Which benefits, limitations and possible adverse effects apply to my situation?

A console name cannot answer those questions on its own. If you are considering treatment in Seoul, Delight Dermatology Clinic’s Ultherapy consultation overview explains the consultation process. Ask the provider to identify the console used for your appointment.

Frequently asked questions

Primary sources

1. US Food and Drug Administration. K233996: Ulthera System (UC-1 Control Unit PRIME), decision letter and 510(k) summary. February 22, 2024.
2. Merz Aesthetics / Ultherapy. Meet Ultherapy PRIME: official manufacturer product page for physicians.